Takeda Archives

News Jun. 15, 2020, 10:38 PM

Dispensed Daily: Developing a coronavirus drug based on patients’ blood — COVID-19’s effects on the nervous system — Economic assistance programs are ending

Hello, Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider. If we haven’t met yet, my name’s Lydia Ramsey Pflanzer, and I’m a healthcare editor here at Business Insider. I typically write our weekly healthcare newsletter,Dispensed. We’re testing out a new daily format for our BI […]

News Dec. 15, 2018, 2:00 AM

Healthcare deals hit an all-time record in 2018. See the 7 biggest tie-ups that could change how we buy drugs and treat diseases.

Healthcare dealmaking hit a record this year, and the transactions could reshape how we pay for our prescriptions and treat diseases. Big pharma companies, health insurers, and care providers have agreed to about $US421 billion in transactions this year, according to data from Refinitiv. That’s a record high, and amounts […]

Markets Apr. 25, 2018, 5:12 PM

Takeda is closing in on buying Adderall maker Shire for $64 billion in pharma’s biggest deal of the year

Takeda has reached a deal to buy Adderall drugmaker Shire for $US64.3 billion. The deal comes after a handful of rejections from Shire and a short-lived potential for a bidding war between Takeda and Botox-maker Allergan. A transaction between Shire and Takeda is the largest pharma deal of the year. […]

Markets Apr. 20, 2018, 11:32 PM

Takeda’s considering turning up the heat on its bid for Shire

Takeda is considering a new bid for Adderall drugmaker Shire, raising the share price to 47 British pounds (about $US66) per share up from 46.50 per share (about $US65), Bloomberg reported Friday. Shire has already turned down three offers from the Japanese pharmaceutical company, the last of which was a […]

Markets Apr. 20, 2018, 12:07 AM

A bidding war for the maker of Adderall stalled out after just 4 hours

Shire rejected Takeda‘s $US60 billion takeover bid on Thursday morning. Allergan then confirmed it was “in the early stages of considering a possible offer” for Shire, potentially creating a bidding war for the $US50 billion drugmaker. That sent Allergan’s stock price spiraling, down more than 8%. Allergan said Thursday afternoon […]